935. Efficacy of Improved Hydrogen Peroxide Disinfectants Against Important Healthcare-Associated Pathogens
Session: Poster Abstract Session: Disinfection and Sterilization
Friday, October 19, 2012
Room: SDCC Poster Hall F-H
Posters
  • 935 University of North Carolina.pdf (7.7 MB)
  • Background:

    To assess the antimicrobial activity of two improved hydrogen peroxide (IHP) products (OxivirTB and Clorox HealthcareTM Hydrogen Peroxide Cleaner Disinfectant wipes) against key healthcare-associated pathogens.  In addition, we compared these products to 3% hydrogen peroxide, a quaternary ammonium compound, and diluted concentrations of 3% hydrogen peroxide (0.5% and 1.4%).

    Methods:

    A quantitative carrier test was used to determine the bactericidal activity of the formulations.  The tested pathogens included methicillin-resistant Staphylococcus aureus; vancomycin-resistant Enterococcus; and a multidrug-resistant (MDR) Acinetobacter baumannii.  The efficacy was assessed using log10 reductions after 30 seconds and 1 minute exposure to the disinfectant with or without an organic material challenge.

    Results:

    Improved hydrogen peroxide eliminated greater than >6-log10 reduction of all test organisms in 30 seconds in the absence of organic material and 1 minute in the presence of organic material.  There was no significant difference between the two tested improved hydrogen peroxides but both products were significantly superior to standard hydrogen peroxide at the same concentration (i.e., 0.5%, 1.4%) or higher concentrations (3%).  The improved hydrogen peroxides were superior or similar to the QUAT tested.

    Conclusion: Improved hydrogen peroxide is significantly superior to standard HP at the same concentration and offers an option for low-level disinfection of non-critical environmental surfaces and patient equipment.  It addresses some of the concerns associated with some other low-level disinfectants (e.g., toxicity, a contact time of >30-60 seconds).

    William Rutala, PhD, FSHEA, Division of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC, Maria Gergen, Department of Hospital Epidemiology, University of North Carolina Health Care, Chapel Hill, NC and David J. Weber, MD, MPH, FIDSA, FSHEA, University of North Carolina, Chapel Hill, NC

    Disclosures:

    W. Rutala, Clorox: Consultant, Consulting fee
    Advanced Sterilization Products: Consultant, Consulting fee
    3M: Speaker, Speaker honorarium

    M. Gergen, None

    D. J. Weber, Clorox: Consultant, Consulting fee
    CDC: Grant Investigator, Research grant

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.